Form D · Biotechnology
Sensei Biotherapeutics, Inc.
Rockville, MD · CIK 0001829802
Offering snapshot reported Mar 4, 2026 · SEC filing
- Reported sold
- $349M Offering amount: $349M
- Investors reported
- 104 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 4, 2026 | Initial | $348,906,500 | No comparison | 104 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $11.7M
- Finders' fees
- $100K
- Form D file number
- 021-575467
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners | 39011 |
Source: Form D, filed Mar 4, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Josiah Craver | Executive |
| Phillip B. Donenberg | Director |
| Christopher Gerry | Director, Executive |
| Bob Holmen | Director |
| Kristian Humer | Director |
| Anand Kiran Parikh | Director, Executive |
| Tom Ricks | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1405 Research Blvd, Suite 125
Rockville, MD, 20850
Rockville, MD, 20850